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Abstract
Introduction: With the goal of eliminating hepatitis C virus (HCV) as a public health problem in Washington State, Public
Health–Seattle & King County (PHSKC) designed a Hepatitis C Virus Test and Cure (HCV-TAC) data system to integrate
surveillance, clinical, and laboratory data into a comprehensive database. The intent of the system was to promote identification, treatment, and cure of HCV-infected persons (ie, HCV care cascade) using a population health approach.
Materials and Methods: The data system automatically integrated case reports received via telephone and fax from health
care providers and laboratories, hepatitis test results reported via electronic laboratory reporting, and data on laboratory and
clinic visits reported by 6 regional health care systems. PHSKC examined patient-level laboratory test results and established
HCV case classification using Council of State and Territorial Epidemiologists criteria, classifying patients as confirmed if they
had detectable HCV RNA.
Results: The data enabled PHSKC to report the number of patients at various stages along the HCV care cascade. Of 7747
HCV RNA-positive patients seen by a partner site, 5377 (69%) were assessed for severity of liver fibrosis, 3932 (51%) were
treated, and 2592 (33%) were cured.
Practice Implications: Data supported local public heath surveillance and HCV program activities. The data system could
serve as a foundation for monitoring future HCV prevention and control programs.
Keywords
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An estimated 4.1 million adults in the United States had
previously been or were currently infected with hepatitis C
virus (HCV) during 2013-2016.1 The number of persons with
acute HCV infection increased about 3.5-fold from 2010 to
2016 (from 850 to 2967 reported cases), largely reflecting the
rising rate of injection drug use and, to a lesser extent,
improved case detection.2 In the United States, the number
of persons with chronic HCV infection is increasing and is
most prevalent among persons born during 1945-1965 (ie,
baby boomers). Because most currently infected persons
were unknowingly exposed decades ago, morbidity and mortality are expected to increase in the coming decades.3 Given
the increasing prevalence of HCV infection, the Centers for
Disease Control and Prevention (CDC) and the US Preventive Services Task Force recommend that baby boomers
receive a 1-time HCV antibody test to identify HCV infection (hereinafter, birth-cohort testing).4,5

In the context of the high burden of chronic HCV infections and the availability of highly effective therapies, a
challenge is to identify infected persons and link them to
care and treatment. Public health departments can facilitate
case identification and linkage to care; however, existing
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databases often lack longitudinal laboratory and clinical
data. These data gaps result in problems with determining
whether a report is confirmed, probable, or not a case, and
they limit health departments’ ability to determine whether
patients have been linked to care, treated, or cured. To
address these gaps, Public Health–Seattle & King County
(PHSKC) developed a comprehensive HCV surveillance system. We provide an overview of the development of this
system—its design, data collection strategies, database, and
analytic issues—with a focus on how the data are being used
to monitor trends and address gaps in the progression from
HCV diagnosis to treatment and cure (hereinafter, the HCV
care cascade) in Seattle–King County, Washington.

Materials and Methods
Surveillance Program and Data System
The CDC-supported PHSKC Hepatitis C Virus Test and
Cure (HCV-TAC) program was originally funded from
September 30, 2014, through September 29, 2018, and
comprised 9 entities: PHSKC; the Hepatitis Education
Project, an organization that provides hepatitis testing, educational outreach, and medical case management services6;
the University of Washington; and 6 community-based clinical sites in King County (Neighborcare Community Health
Centers, HealthPoint Community Health Centers, Country
Doctor Community Health Centers, Swedish Medical
Center, Harborview Medical Center, and Kaiser Permanente
Washington).
The 4 goals of HCV-TAC were to (1) increase and monitor the number of persons at risk for HCV infection who are
tested, receive care and treatment, and are cured; (2) increase
primary care providers’ capacity to diagnose and cure HCV
infection through the expansion of a telehealth HCV clinical
training network (Project ECHO [Extension for Community
Healthcare Outcomes]7) and online training for health care
providers8; (3) establish networks of HCV specialists and
primary care providers to develop and implement services
for subpopulations with high rates of HCV infection; and (4)
support and evaluate efforts to reduce HCV infections and
provide best practices that can be applied elsewhere.
During the program period, we integrated surveillance,
clinical, and laboratory data into a comprehensive database
that supported the program’s objectives. PHSKC used these
data to monitor HCV incidence in King County, enhance
HCV testing efforts among target populations, track progress
in the care cascade, and support patient linkage to care.

Data Sources
Acute HCV infection and chronic HCV infection are nationally9 and locally10 notifiable diseases. All health care providers and laboratories in Washington State are legally
required to report cases to public health departments.
PHSKC’s data system integrated (1) hepatitis case reports
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received via telephone and fax from health care providers
and laboratories (beginning in 2000, these reports were
entered into a local legacy database), (2) hepatitis test results
reported via electronic laboratory reporting (ELR) to the
Washington State Department of Health (WA DOH), and
(3) laboratory and clinic visit data reported by the 6 HCVTAC clinical sites.

Data System Design
PHSKC redesigned its legacy database to improve the timeliness and completeness of reporting. Historically, clinicians
and laboratories submitted hepatitis case reports via telephone and fax. Administrative staff members manually
entered these reports as well as reports from the WA DOH
ELR web portal into the legacy database. Because of
resource constraints (eg, demands on staff time), PHSKC
generally entered only initial case reports for patients into
the legacy database (ie, patients without an existing hepatitis
B or hepatitis C record, based on a search of the patient’s last
name, first name, and date of birth). To minimize the administrative burden of manual data entry and ensure more complete capture of data from laboratory reports, beginning in
2014, HCV-TAC program staff members worked with the
King County Information Technology Department (hereinafter, IT Department) to redesign the hepatitis module of the
legacy database.
PHSKC modified the legacy database from an incidentbased structure (ie, 1 record per acute and chronic HCV
infection event) to a person-based structure (ie, 1 record per
person, with shared demographic, laboratory, and clinical
data across hepatitis events). To achieve this structural modification, PHSKC mapped data elements from ELR and clinical sites to elements in the modified surveillance database.
The IT Department created new fields to accommodate
laboratory elements that did not previously exist in the database, including collection dates and ordering facility/provider information for each laboratory result. We designed a
relational interface to display multiple laboratory reports per
person over time and information captured across multiple
health care visits per person, and we de-duplicated records in
the legacy database to derive a single demographic record
per person. The IT Department created a person-history table
to preserve changes to data on patients’ demographic characteristics over time.
The redesigned database (completed in 2018) enabled
PHSKC to automatically import hepatitis laboratory reports
from the WA DOH ELR system and partner laboratory and
clinical data, eliminating the need for manual data entry.
Algorithms compare data on patient demographic characteristics from incoming reports with existing patient records.
Incoming data for patients matching an existing record (ie,
with a matching score above a defined threshold) are
appended to that record. A new record is created when it is
determined that a patient does not already exist in the database (ie, with a matching score below a defined threshold).
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The system holds records deemed ambiguous matches for
manual review and de-duplication.

Target Populations
PHSKC designed the HCV-TAC program in 2013 to serve
target populations disproportionately affected by HCV. The
6 health care facilities that partnered with the HCV-TAC
program serve an estimated 140 000 of 520 000 (27%) baby
boomers in King County. PHSKC selected these clinical sites
to serve a broad geographic and demographic distribution of
HCV patients. Three of the clinical sites (HealthPoint,
Neighborcare, and Country Doctor) are federally qualified
health centers (FQHCs) and are the largest providers of primary medical and dental care in Seattle for low-income and
uninsured patients; in 2014, roughly 30% of patients at each
site were uninsured.11 Many FQHC patients were recent
immigrants, and the population was racially and ethnically
diverse (in 2014, racial and/or ethnic minority groups
accounted for 67% of patients at HealthPoint, 60% of
patients at Country Doctor, and 70% of patients at Neighborcare).11 Harborview Medical Center is an urban public
hospital primarily serving medically underserved patients,
including immigrants, persons who inject drugs, and persons
with HIV. Harborview’s Hepatitis and Liver Clinic is the
largest provider of HCV care in the Pacific Northwest. Swedish Medical Center comprises 5 hospitals and 100 clinics in
King County, including a liver transplant program, and
serves more than 100 000 King County primary care patients.
Kaiser Permanente is a not-for-profit health plan that serves
more than 200 000 residents in King County, including Medicaid and uninsured patients. All HCV-TAC clinical sites
allow HCV treatment for current substance users.
During the program period, the 6 HCV-TAC clinical sites
submitted data for King County patients who were (1) known
to have HCV infection, defined as the presence of a record
documenting a previous clinical HCV diagnosis, a positive
HCV laboratory test result (antibody, RNA, or genotyping),
or history of being treated for HCV infection; (2) born during
1945-1965, tested for HCV infection, and HCV antibody
negative; and (3) born during 1945-1965 and did not have
records of HCV testing. In 2013, PHSKC instructed clinical
sites to reach back as far as possible in their electronic health
records (EHRs) to determine eligibility for each subset; sites
reported identifiers only for patients known to have HCV
infection.

Frequency and Format of Data Collection
Clinical sites submitted historical data to PHSKC that dated
back to January 1, 2013, and began quarterly reporting of
laboratory and clinical data in 2015. Because of administrative delays in finalizing laboratory results and billing diagnoses, some sites had up to a 4-month lag in transmitting
complete quarterly data.
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WA DOH transmitted hepatitis data to PHSKC reported
through its ELR system in Extensible Markup Language
(XML) format on a weekly basis. These data included all
King County laboratory reports submitted to WA DOH (ie,
not restricted to the 6 HCV-TAC clinical sites). PHSKC
asked clinical sites to report data in XML file format to
ensure uniformity in data submission and allow the IT
Department to upload data without creating a separate upload
process for each site. The IT Department uploaded historical
ELR data to the modified database dating back to January 1,
2013. Laboratories not yet participating in ELR submitted
hepatitis reports to PHSKC by fax daily; PHSKC administrative staff members manually reviewed data on patient
demographic characteristics to determine whether cases had
been previously reported and manually entered laboratory
reports into the modified database.

Data Elements in the Modified Database
Laboratory reports for HCV patients included the following
results, where available: HCV antibody tests (positive results
only), HCV antibody detection signal-to-cutoff ratio (which
helps identify true-positive results), all qualitative and quantitative HCV RNA test results (including negative and indeterminate findings), HCV genotype, liver enzyme tests
(including alanine aminotransferase [ALT], aspartate aminotransferase [AST], and platelets), all FibroSure results
(which measure level of scarring to the liver, including
necroinflammatory activity score and grade and fibrosis
score and stage), and positive hepatitis A and hepatitis B
serology results. Beginning in 2013, PHSKC asked laboratories to submit only ALT, AST, platelets, and hepatitis A/
hepatitis B serology results ordered on the same day or
within 1 month of a positive hepatitis C test, if possible,
because providers may have ordered these tests for reasons
other than managing HCV care.
The 6 HCV-TAC clinical sites extracted patient encounter
data from their EHRs for quarterly submission to PHSKC.
These files included the following data elements: name,
birthdate, social security number, visit date, provider, clinic,
patient’s health insurance at that visit, comorbidities listed at
that visit, treatment history, medical history, assessment
notes, plan notes, HCV medications the patient was currently
taking or prescribed at that visit (including start/stop dates),
and treatment outcome (eg, achieved cure, treatment failure,
treatment discontinued, lost to follow-up). For the subset of
patients identified by the clinical sites who tested negative
for HCV, and for those who had never been tested, deidentified visit-level data consisted of visit date, provider,
clinic, race, ethnicity, and county of residence. These data
were not attached to a patient’s records in the database. Sites
with multiple clinic locations queried all locations for HCVrelated visits at that site to identify patients.
Case managers and disease investigators entered data on
patient encounters into the modified database, including the
aforementioned laboratory and clinical data elements (if not
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already recorded) and dates and times of case management
outreach attempts and outcomes (eg, lost to follow-up, linked
to care, already in care, refused care, not actively infected,
out of jurisdiction, deceased, not eligible for case management, in process).

Data Analysis and Reporting
PHSKC epidemiologists analyzed the HCV-TAC data at
least quarterly by using SAS version 9.4.12 They parsed
laboratory data using Logical Observation Identifiers Names
and Codes and local codes to identify the type of hepatitis
tests conducted. Using a hierarchical combination of Systemized Nomenclature of Medicine and local result codes, epidemiologists classified result values across disparate fields
(eg, abnormal result flags, text queries, and numerical values) to a standardized format. They transformed the data to
display all tests performed per patient over time as a single
observation. PHSKC established case classification according to the current Council of State and Territorial Epidemiologists criteria13 by examining data on laboratory and clinical
results extracted from the patient’s entire medical record.
PHSKC classified patients as confirmed if they had detectable HCV RNA. PHSKC identified potential acute HCV
cases based on a newly positive HCV antibody test combined
with elevated ALT/AST results. To help differentiate
between acute HCV infection and chronic HCV infection,
PHSKC staff members contacted the ordering provider and
reviewed health records to identify the reason for testing and
applicable risk factors.
PHSKC reported de-identified patient-level data to CDC
quarterly for monitoring and evaluation of the project.
PHSKC monitored patient progress on the HCV care cascade, including confirmatory RNA test results, staging (genotype test or fibrosis staging test), treatment start date,
treatment completion, and 12-week posttreatment testing for
cure. PHSKC classified patients as cured based on an HCV
RNA negative result at 12 weeks posttreatment or based on
reporting of cures in the clinical data. Epidemiologists analyzed discrepancies between laboratory data and clinical data
to determine patient outcomes (ie, infected, cured, or reinfected) based on the timing of the report.
PHSKC created quarterly reports for the 6 participating
health care clinics that summarized their HCV patient populations and proportion at each step of the HCV care cascade
and provided patient-level reports to sites to help identify
patients requiring linkage to care or other clinical follow-up.
To evaluate each clinic’s performance with birth-cohort
HCV testing, PHSKC created a data set representing all
clinic visits and associated laboratory results among the
entire birth-cohort population. We identified patients with
at least 1 primary care visit during a specified period
(denominator), and we used laboratory data to determine the
percentage of these patients screened for HCV antibody
before or during that period (numerator). Epidemiologists
used these data to calculate the percentage of screened
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birth-cohort members for each site and at all sites combined
over time.

Results
PHSKC’s legacy database was poorly suited for chronic
HCV surveillance: it lacked key laboratory, clinical, and
demographic data elements for identifying and tracking
HCV cases longitudinally during multiple clinical encounters (Table).
Importing all hepatitis test results reported to WA DOH
via ELR into the modified database improved PHSKC’s ability to identify cases relative to the legacy database. PHSKC
identified a cumulative 22 814 confirmed cases of HCV
infection in King County that were manually entered into
the database from January 1, 1991, through July 31, 2018.
From January 1, 2013, through July 31, 2018, PHSKC identified an additional 3727 confirmed cases by automatically
uploading the state’s hepatitis ELR data into the modified
database. Because of efforts by WA DOH to improve ELR,
combined with HCV-TAC efforts asking participating
laboratories to report additional hepatitis results, the proportion of HCV laboratory test results reported through ELR
increased annually from 2013 to 2017. The percentage of
hepatitis laboratory results received by PHSKC each year
that were reported through ELR was 60% in 2013, 65% in
2014, 69% in 2015, 82% in 2016, and 94% in 2017.
The retrospective collection of laboratory data from
HCV-TAC partners enhanced the completeness of case identification. We identified 1045 confirmed cases of HCV infection from partner data that we did not identify via manual
reporting from laboratories and health care providers or ELR
from January 1, 2013, through July 31, 2018. Some reports
were from partners that were not yet participating in ELR at
the start of the project.
PHSKC used its modified data system to describe changes
in HCV screening longitudinally (eg, the percentage of
screened patients in the birth cohort). The data system also
enabled us to create a care cascade to assess the percentage of
patients diagnosed, staged, genotyped, prescribed treatment,
and cured among our partner sites. Of 27 586 confirmed
cases of HCV infection in King County, 7747 (28%) were
seen at our partner sites and were HCV RNA positive. Of
these 7747 confirmed cases, 5377 (69%) had genotype or
fibrosis staging results, 3932 (51%) were prescribed HCV
treatment based on clinical data, and 2572 (33%) were cured
at 12 weeks after the estimated completion of treatment.

Discussion
The US National Viral Hepatitis Action Plan for 2017-2020
calls for the elimination of viral hepatitis and development of
robust surveillance and health information systems14 for
evaluating trends in HCV case identification and cure. The
PHSKC HCV-TAC data system enhanced the completeness
and usefulness of population-level HCV surveillance data,
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Table. Attributes of Public Health—Seattle & King County’s data system for hepatitis C surveillance, clinical, and laboratory data before and
after implementation of the Hepatitis C Virus Test and Cure (HCV-TAC) programa
Attribute

Before

After

Database design

 Incident-based SQL database, with separate records for
each hepatitis event

 Person-based SQL database, with shared demographic,
laboratory, and clinical data across hepatitis events

Data sources

 Case reports received via telephone and fax from health
care providers and laboratories

 Case reports received via telephone and fax from health
care providers and laboratories
 Hepatitis test results reported via electronic laboratory
reporting to WA DOH
 Laboratory and clinic visit data reported by the 6 clinical
partner sites in the HCV-TAC coalition

Time frame

 Surveillance records from manual reporting dating to 2000  Historical surveillance records from manual reporting
dating to 2000, merged with data captured from electronic
laboratory reporting and HCV-TAC partner reporting
beginning in 2013

Data capture

 Administrative staff members manually reviewed and
entered hepatitis reports submitted by clinicians and
laboratories via telephone and fax or entered reports
downloaded from the WA DOH electronic laboratory
reporting web portal

 Automated capture of data from electronic laboratory
reporting and HCV-TAC partner sites

Longitudinal data
collection

 No capture of historical demographic information
 One specimen collection date; placeholders for a single
HCV antibody and HCV RNA result
 Single placeholder for name and telephone number of
health care provider

 Person-history table preserves changes in patients’
demographic characteristics over time
 Specimen collection dates and results for each test
reported through electronic laboratory reporting or HCVTAC partners
 Details for each HCV-related clinical visit reported by
HCV-TAC partners

De-duplication

 Manual

 Algorithm-based matching of incoming records against
persons in database; manual review of subset of records
where algorithm score suggested an ambiguous match

Laboratory reporting

 Typically, PHSKC entered only first reports. PHSKC asked  PHSKC captured all reported results. Laboratories
reported the following results, when available: HCV
laboratories to report positive HCV antibody and HCV
antibody tests (positive results only); HCV antibody
RNA results, as well as signal-to-cutoff ratios.
detection signal-to-cutoff ratio; qualitative and quantitative
HCV RNA test results (including negative and
indeterminate findings); HCV genotype; liver enzyme tests
(including alanine aminotransferase, aspartate
aminotransferase, and platelets); FibroSure (including
necroinflammatory activity score and grade, and fibrosis
score and stage); hepatitis A and B serology results.

Clinical reporting

 Single placeholder for provider and facility name

 Dates, provider and clinic names, insurance, comorbidities,
vaccination status, treatment history, medical history,
assessment notes, plan notes, and treatment (including
medication names, start/stop dates, and treatment
outcome) for each visit reported

Case management

 Free-text notes only

 Dates and times of PHSKC case management outreach
attempts and outcomes

Ability to monitor
population HCV
screening targets

 No

 For HCV-TAC partner sites only; de-identified data
collected for patients who were tested and were HCV
negative and for patients who were never screened; these
data were captured in a separate database to assess clinical
sites’ progress toward screening their baby boomer (ie,
born during 1945-1965) patient population for HCV

Ability to generate
 No
HCV care cascades

 For HCV-TAC partner sites only

Abbreviations: HCV, hepatitis C virus; PHSKC, Public Health–Seattle & King County; SQL, structured query language; WA DOH, Washington State
Department of Health.
a
The HCV-TAC program was funded by the Centers for Disease Control and Prevention during 2014-2018. The program aimed to integrate surveillance,
clinical, and laboratory data into a comprehensive database to promote the identification, treatment, and cure of HCV-infected persons using a population
health approach.
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allowing PHSKC to monitor HCV testing and treatment targets in King County. These data enabled PHSKC to determine how many patients were screened for HCV and the
percentage who were infected, staged, treated, and cured.
The data also allowed PHSKC to evaluate longitudinal
changes relative to baseline (the start of the project in
2013). These analyses were not feasible before implementing
this data system. PHSKC continues to collect data and support analyses using the data system beyond the original funding period, which ended in 2018. This information will
enable PHSKC to identify disparities in HCV diagnosis,
initiation of treatment, and treatment outcomes and to
develop targeted interventions.
An additional benefit of the data system was that provision of reports created by PHSKC to facilitate monitoring
and coordination of clinical care increased collaboration with
clinicians caring for HCV-infected persons. The integration
of data received from multiple health care facilities and
laboratories in King County into a single database has aided
epidemiologists, clinicians, and case managers, who would
otherwise be required to extract data from multiple systems
to obtain comprehensive patient summaries necessary for
monitoring progress through the chronic HCV infection care
cascade.

Limitations
This system had several limitations. Differences in the way
each clinical site’s EHR captures information created challenges in data ascertainment and interpretation. First, providers do not record some information reliably or in a
standardized format, including history of substance use or
HCV treatment, and sometimes this information can be
found only in free-text notes, not structured fields, depending
on the EHR. Second, treatment start dates in EHRs generally
represent dates on which providers ordered prescriptions, not
necessarily the date on which the first dose was taken, and
providers do not consistently document treatment end dates
in structured fields. The treatment end date is currently considered important for assessing treatment outcomes because
guidelines state that HCV RNA must be undetected at
12 weeks after treatment is completed to establish whether
the patient was cured. When the start date and end date for a
derived treatment are incorrect, a treatment outcome may be
misclassified. Lastly, information on the clinical stage of
liver disease based on methods such as AST to Platelet Ratio
Index, FibroSure, liver biopsy, and Fibroscan results may be
available only as scanned documents and cannot be queried
directly during data extraction. Some sites extracted staging
data manually from scanned documents; however, this activity is likely unsustainable because it requires trained
reviewers and is resource intensive.
Another limitation of our data system was that fewer than
one-third (7747 of 27 856; 28%) of all confirmed patients
with HCV infection in King County were seen at one of our
partner sites. Funding for this project allowed us to collect
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clinical data from only a subset of regional health care facilities, which limited our ability to identify all patients who
had been treated and subsequently cured in King County.
Although it is technically feasible to recruit additional sites
to submit clinical data, doing so would require resources for
onboarding expenses (eg, for structural and content validation), which is a barrier to system expansion. Public health
jurisdictions that are unable to capture clinical data for surveillance can rely on laboratory data alone to identify
patients requiring linkage to care (eg, patients with a positive
HCV RNA result who do not have HCV staging laboratory
results) and to monitor for markers of cure (eg, a positive
HCV RNA result followed by a negative HCV RNA result
after a minimum of 12 weeks). Approaches and limitations of
using proxy measures to measure treatment outcomes have
been described previously.15,16 More than 30% of patients
seen at HCV-TAC partner sites (1360 of 3932) who
started treatment did not have follow-up HCV RNA results
12 weeks after their estimated treatment completion date;
as such, the percentage of patients identified as cured was
likely underestimated.
Lastly, because PHSKC collected only de-identified data
for HCV antibody–negative patients and patients never
tested for HCV, there were limitations in assessing birthcohort HCV screening. The lack of patient identifiers means
that PHSKC cannot de-duplicate data across sites or against
existing surveillance records to identify persons screened
elsewhere, which may result in an underestimation of the
proportion of the population screened for HCV.

Practice Implications
Historically, laboratories and health care providers reported
cases of acute and chronic HCV infection to PHSKC by
telephone and fax. Because of the large volume of reports
and limited resources, staff members entered only first
reports for cases of HCV infection into PHSKC’s legacy
surveillance database. The CDC-funded HCV-TAC program
enabled PHSKC to modify its public health surveillance
database to incorporate data from ELRs and clinical data
extracted from EHRs. Integrating these data sources provided additional information about confirmatory testing, staging, and treatment response, which PHSKC was not
previously able to identify. Combined with clinical visit
information that was previously available only through
labor-intensive medical record review, the redesigned database facilitates optimal public health, health care system, and
clinical management of chronic HCV infection to improve
population health and to support ongoing local HCV elimination program needs. This system has the potential to serve
as the foundation for monitoring future HCV prevention and
control programs.
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